These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 34351918)

  • 1. PON1 Q192R is associated with high platelet reactivity with clopidogrel in patients undergoing elective neurointervention: A prospective single-center cohort study.
    Tanaka K; Matsumoto S; Ainiding G; Nakahara I; Nishi H; Hashimoto T; Ohta T; Sadamasa N; Ishibashi R; Gomi M; Saka M; Miyata H; Watanabe S; Okata T; Sonoda K; Koge J; Iinuma KM; Furuta K; Nagata I; Matsuo K; Matsushita T; Isobe N; Yamasaki R; Kira JI
    PLoS One; 2021; 16(8):e0254067. PubMed ID: 34351918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome.
    Peng W; Shi X; Xu X; Lin Y
    Cardiovasc Ther; 2019; 2019():3470145. PubMed ID: 31772608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity.
    Li X; Zhang L; Chen X; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Xu Q; Zhang Y; Li Y; Lu C; Yin T
    Thromb Res; 2013 Oct; 132(4):444-9. PubMed ID: 23993903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relationship between clopidogrel resistance and genetic variability in Kawasaki disease children with coronary artery lesions].
    Cao YY; Pan QY; Li J; Zhong XF; Liang XC; He L; Chu C; Zhao QM; Zhao L; Wang F; Sun SN; Lin YX; Huang GY; Liu F
    Zhonghua Er Ke Za Zhi; 2024 Oct; 62(10):981-988. PubMed ID: 39327966
    [No Abstract]   [Full Text] [Related]  

  • 5. Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement.
    Trenk D; Hochholzer W; Fromm MF; Zolk O; Valina CM; Stratz C; Neumann FJ
    Circ Cardiovasc Genet; 2011 Aug; 4(4):429-36. PubMed ID: 21685174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between Paraoxonase-1 p.Q192R Polymorphism and Coronary Artery Disease susceptibility in the Colombian Population.
    Corredor-Orlandelli D; Sambracos-Parrado S; Mantilla-García S; Tovar-Tirado J; Vega-Ramírez V; Mendoza-Ayús SD; Peña LC; Leal MF; Rodríguez-Carrillo J; León-Torres J; Pardo-Oviedo JM; Parra Abaunza K; Contreras Bravo NC; Ortega-Recalde O; Fonseca Mendoza DJ
    Vasc Health Risk Manag; 2021; 17():689-699. PubMed ID: 34764653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention.
    Saiz-Rodríguez M; Belmonte C; Caniego JL; Koller D; Zubiaur P; Bárcena E; Romero-Palacián D; Eugene AR; Ochoa D; Abad-Santos F
    Clin Ther; 2019 Jun; 41(6):1199-1212.e2. PubMed ID: 31128980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].
    Cano P; Consuegra-Sánchez L; Conesa P; Torres-Moreno D; Jaulent L; Dau D; Picó F; Villegas M
    Med Clin (Barc); 2014 Jul; 143(1):6-12. PubMed ID: 23850044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
    Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A
    Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paraoxonase-1 Q192R polymorphism is not associated with clopidogrel response in Chinese stroke patients.
    Yang J; Zhou JS; Tan J; He BS; Zou JJ
    Pharmazie; 2012 Dec; 67(12):1026-9. PubMed ID: 23346768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Platelet REACtivity After Transcatheter Aortic Valve Replacement: The REAC-TAVI Trial.
    Jimenez Diaz VA; Tello-Montoliu A; Moreno R; Cruz Gonzalez I; Baz Alonso JA; Romaguera R; Molina Navarro E; Juan Salvadores P; Paredes Galan E; De Miguel Castro A; Bastos Fernandez G; Ortiz Saez A; Fernandez Barbeira S; Raposeiras Roubin S; Ocampo Miguez J; Serra Peñaranda A; Valdes Chavarri M; Cequier Fillat A; Calvo Iglesias F; Iñiguez Romo A
    JACC Cardiovasc Interv; 2019 Jan; 12(1):22-32. PubMed ID: 30621974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
    Braun OÖ; Angiolillo DJ; Ferreiro JL; Jakubowski JA; Winters KJ; Effron MB; Duvvuru S; Costigan TM; Sundseth S; Walker JR; Saucedo JF; Kleiman NS; Varenhorst C
    Thromb Haemost; 2013 Dec; 110(6):1223-31. PubMed ID: 24009042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Both PON1 Q192R and CYP2C19*2 influence platelet response to clopidogrel and ischemic events in Chinese patients undergoing percutaneous coronary intervention.
    Chen Y; Huang X; Tang Y; Xie Y; Zhang Y
    Int J Clin Exp Med; 2015; 8(6):9266-74. PubMed ID: 26309584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clopidogrel-associated genetic variants on inhibition of platelet activity and clinical outcome for acute coronary syndrome patients.
    Li X; Wang Z; Wang Q; Xu Q; Lv Q
    Basic Clin Pharmacol Toxicol; 2019 Jan; 124(1):84-93. PubMed ID: 30098132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.
    Hulot JS; Collet JP; Cayla G; Silvain J; Allanic F; Bellemain-Appaix A; Scott SA; Montalescot G
    Circ Cardiovasc Interv; 2011 Oct; 4(5):422-8. PubMed ID: 21972404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response.
    Kreutz RP; Nystrom P; Kreutz Y; Miao J; Desta Z; Breall JA; Li L; Chiang C; Kovacs R; Flockhart DA; Jin Y
    Clin Pharmacol; 2012; 4():13-20. PubMed ID: 22427735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.
    Tresukosol D; Suktitipat B; Hunnangkul S; Kamkaew R; Poldee S; Tassaneetrithep B; Likidlilid A
    PLoS One; 2014; 9(10):e110188. PubMed ID: 25329996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
    Saucedo JF; Angiolillo DJ; DeRaad R; Frelinger AL; Gurbel PA; Costigan TM; Jakubowski JA; Ojeh CK; Duvvuru S; Effron MB;
    Thromb Haemost; 2013 Feb; 109(2):347-55. PubMed ID: 23223867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention.
    Ono T; Kaikita K; Hokimoto S; Iwashita S; Yamamoto K; Miyazaki Y; Horio E; Sato K; Tsujita K; Abe T; Deguchi M; Tayama S; Sumida H; Sugiyama S; Yamabe H; Nakamura S; Nakagawa K; Ogawa H
    Thromb Res; 2011 Dec; 128(6):e130-6. PubMed ID: 21862109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switch to Ticagrelor in critical limb ischemia antiplatelet study (STT-CLIPS).
    Clavijo LC; Dhillon A; Al-Asady N; Matthews RV; Caro J; Tun H; Rowe V; Shavelle DM
    Cardiovasc Revasc Med; 2018; 19(3 Pt B):319-323. PubMed ID: 29329963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.